Treating bone marrow cancers linked to PARP inhibitor use in ovarian cancer survivors
Therapy of PARP inhibitor-associated myeloid neoplasms in ovarian cancer patients
Researchers are developing new drug strategies to treat aggressive bone marrow cancers that can occur after PARP inhibitor therapy in ovarian cancer survivors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11308742 on NIH RePORTER |
What this research studies
This project focuses on bone marrow disorders (myelodysplastic syndrome and acute myeloid leukemia) that can arise after ovarian cancer patients receive PARP inhibitor drugs. The team is studying why these cancers often have TP53 gene defects and is testing drugs that block DNA‑damage checkpoints (CHK1, WEE1, and ATR inhibitors) in lab-grown cells, mouse tumor models, and patient leukemia samples. The goal is to find treatments that work against these hard-to-treat, TP53‑mutant cases and to identify which patients might benefit. Promising results would support moving these approaches toward clinical testing.
Who could benefit from this research
Good fit: Ideal candidates are ovarian cancer survivors who develop therapy-related myelodysplastic syndrome or acute myeloid leukemia after PARP inhibitor treatment, especially those whose leukemia shows TP53 inactivation.
Not a fit: Patients without therapy-related myeloid neoplasms or whose leukemia is unrelated to prior PARP inhibitor exposure or driven by different genetic changes may not benefit from this work.
Why it matters
Potential benefit: Could lead to new therapies that improve survival and reduce relapse for ovarian cancer survivors who develop PARP inhibitor–associated myeloid neoplasms.
How similar studies have performed: Preclinical studies of replication checkpoint inhibitors have shown antileukemic effects in cell lines, animal models, and patient samples, but their clinical benefit in humans remains unproven.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Kaufmann, Scott H — Mayo Clinic Rochester
- Study coordinator: Kaufmann, Scott H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.